ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
Jun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
Aug 8, 2024 · New results from the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 phase 3 study show that Sarclisa (Isatuximab-irfc) in combination with lenalidomide, bortezomib, and dexamethasone (RVd) during induction therapy in transplant-eligible, newly diagnosed multiple myeloma (NDMM) …
Press Room - Sanofi US News
Sep 20, 2024 · SARCLISA is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not eligible for transplant.
Press Release: Sarclisa recommended for EU approval by the …
1 day ago · Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma. Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination ...
Sanofi moves on J&J in first-line myeloma with FDA nod
Sep 20, 2024 · Sanofi is developing its own subcutaneous Sarclisa, with a readout from the IRAKLIA trial in the second-line setting expected this year.
Sanofi targets first-line myeloma as Sarclisa delivers trial win
Dec 7, 2023 · Using Sarclisa on top of Takeda’s Velcade, Bristol Myers Squibb’s Revlimid and the steroid dexamethasone (VRd), significantly reduced the risk of disease progression or death versus VRd alone in...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
On Saturday, the FDA approved Sanofi’s SA (NASDAQ: SNY) Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult...
Press Release: Sarclisa recommended for EU approval by the
1 day ago · Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma. Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination ...
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
Sep 20, 2024 · The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult...
FDA approves Sarclisa with bortezomib, lenalidomide, and …
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly...
- Some results have been removed